Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial
Circulation · 2026
DOI: 10.1161/circulationaha.126.079839 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2026. Verfasst von Misa Fister und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Intensive Internal Medicine, University Medical Centre Ljubljana, Slovenia (M.F., M.N., P.R., D.F., T.G.). Hauptthemen laut MEDLINE: Heparin, ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: University Medical Center Ljubljana.
Abstract (Originalsprache)
BACKGROUND: Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for patients with ST-segment–elevation myocardial infarction (STEMI). We investigated the benefits and safety of pretreatment with unfractionated heparin (UFH) in patients with STEMI referred to primary PCI. METHODS: In HEPARIN-STEMI (Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction)—a single-center, open-label, randomized controlled trial—patients with STEMI with ≤6 hours symptom duration were assigned to receive either a 70- to 100-IE/kg bolus of UFH at first prehospital medical contact plus a supplemental dose before PCI, adjusted to activated clothing time ≥250 seconds, or to a control group receiving standard UFH at the time of PCI. The primary efficacy end point was TIMI (Thrombolysis in Myocardial Infarction) flow grade 2–3 in the infarct-related artery at initial coronary angiography. The primary safety end point was BARC (Bleeding Academic Research Consortium) type 3–5 bleeding during the index hospital stay. RESULTS: From March 2022 to February 2025, 298 patients were randomized to UFH pretreatment and 295 to the control group. The groups were comparable in age, sex, risk factors, previous cardiovascular events, and median delay from symptoms to coronary angiography (145 versus 150 minutes; P =0.814). The median time from UFH pretreatment to coronary angiography was 60 minutes (25th–75th interquartile range, 47–55 minutes). TIMI flow grade 2–3 in the infarct-related artery was documented in 43% of patients with UFH pretreatment and 27% of patients in the control group (relative risk, 1.59 [95% CI, 1.27–1.98]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Intensive Internal Medicine, University Medical Centre Ljubljana, Slovenia (M.F., M.N., P.R., D.F., T.G.).
- Clinical Department of Cardiology, University Medical Centre Ljubljana, Slovenia (M.B.). Medical Faculty, University of Ljubljana, Slovenia (M.F., M.N., P.R., M.B., T.G.).
- Department of Advanced Biomedical Science, University of Naples "Federico II," Naples, Italy (D.F.).
ORCID-Profile: Misa Fister, Marko Noc, Matjaz Bunc, Danilo Franco, Tomaz Goslar
Förderung
- University Medical Center Ljubljana
Zitieren
APA
Fister, M., Noc, M., Radsel, P., Bunc, M., Franco, D., Goslar, T., & HEPARIN-STEMI Trial (2026). Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.126.079839
Vancouver
Fister M, Noc M, Radsel P, Bunc M, Franco D, Goslar T, et al. Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial. Circulation. 2026. doi:10.1161/circulationaha.126.079839
BibTeX
@article{Fister2026,
author = {Fister, Misa and Noc, Marko and Radsel, Peter and Bunc, Matjaz and Franco, Danilo and Goslar, Tomaz and HEPARIN-STEMI Trial, HEPARIN-STEMI Trial},
title = {Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.126.079839}
}
EUVIMED